Insulet (NASDAQ:PODD) Earns "Outperform" Rating from Leerink

Leerink Partnrs reissued their outperform rating on shares of Insulet (NASDAQ:PODD – Free Report) in a research note published on Monday, PriceTargets.com reports. Leerink Partnrs also issued estimates for Insulet’s Q3 2023 earnings at $0.44 EPS, Q4 2023 earnings at $0.68 EPS, Q1 2024 earnings at $0.48 EPS, Q2 2024 earnings at $0.69 EPS, Q3 […]

Related Keywords

United States , Manhattan , New York , American , Piper Sandler , James Hollingshead , Leerink Partnrs , Jefferies Financial Group , American National Bank , First Manhattan Co , Securities Exchange Commission , Insulet Company Profile , Quintet Private Bank Europe , Lindbrook Capital , Massmutual Trust Co , Insulet Corporation , Jpmorgan Chase Co , Free Report , Moderate Buy , Get Free Report , Exchange Commission , National Bank , Massmutual Trust , Omnipod System , Insulet Daily , Insulet , Nasdaq Podd , Podd , Medical , 45784p10 , Reiterated Rating ,